{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:06:49Z","timestamp":1784632009349,"version":"3.55.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032339","name":"BioNTech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["BNT162-01"],"award-info":[{"award-number":["BNT162-01"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["BNT162-02"],"award-info":[{"award-number":["BNT162-02"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People with human immunodeficiency virus (HIV) are at increased risk of severe COVID-19 and are recommended for priority vaccination. We investigated the safety and immunogenicity of a 2-dose regimen of the mRNA vaccine BNT162b2 in people with HIV (PWH) on antiretroviral therapy (ART).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Safety, reactogenicity, and immunogenicity data were obtained from PWH on ART \u226516 years enrolled in the phase 1\/2\/3 BNT162-02 trial\/C4591001 (NCT04368728) between September and November 2020, which randomized participants (1:1) to receive BNT162b2 or placebo. Immunogenicity was also investigated in a substudy of the open-label phase 1\/2 BNT162-01 trial (NCT04380701) in PWH aged 18\u201385 years and age- and sex- matched HIV-negative controls enrolled February to March 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 201 PWH were included from the BNT162-02 trial. Higher rates of local and systemic reactions were reported during the 7 days following both doses by participants administered BNT162b2 versus participants administered placebo, most notably pain at injection site, fatigue, headache, and chills. Most reactions were mild to moderate in severity. No serious adverse events occurred up to 1 month post\u2013dose 2. Spike protein\u2013binding and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody responses were elicited in participants who received BNT162b2 and remained above prevaccination baseline levels through 6 months post\u2013dose 2. In the BNT162-01 trial, all PWH (N = 15) seroconverted, with BNT162b2-induced SARS-CoV-2 neutralization titers and longitudinal T-cell responses similar to those observed in the HIV-negative cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Primary 2-dose vaccination with BNT162b2 in PWH was well tolerated and immunogenic with sustained responses up to 6 months, supporting vaccination in this priority population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag310","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:17:54Z","timestamp":1781695074000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety and Immunogenicity of BNT162b2 in Antiretroviral Therapy\u2013Treated People With HIV"],"prefix":"10.1093","volume":"13","author":[{"given":"Essack","family":"Mitha","sequence":"first","affiliation":[{"name":"Newtown Clinical Research , Johannesburg ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mezgebe","family":"Berhe","sequence":"additional","affiliation":[{"name":"North Texas Infectious Diseases Consultants , Dallas, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8162-0284","authenticated-orcid":false,"given":"Judith","family":"Aberg","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai , NewYork, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Lucasti","sequence":"additional","affiliation":[{"name":"South Jersey Infectious Disease , Somers Point, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Chalhoub","sequence":"additional","affiliation":[{"name":"Clinical Neuroscience Solutions , Jacksonville, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-3380","authenticated-orcid":false,"given":"Nicholas","family":"Kitchin","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Ltd , Marlow ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9757-9618","authenticated-orcid":false,"given":"Isabel","family":"Vogler","sequence":"additional","affiliation":[{"name":"Cellular Biomarker and Immunology Research, BioNTech SE , Mainz ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-2193","authenticated-orcid":false,"given":"Stephen P","family":"Lockhart","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Ltd , Hurley ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Cellular Biomarker and Immunology Research, BioNTech SE , Mainz ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9589-9941","authenticated-orcid":false,"given":"Jasmin","family":"Quandt","sequence":"additional","affiliation":[{"name":"Cellular Biomarker and Immunology Research, BioNTech SE , Mainz ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C","family":"Gruber","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Webber","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Ltd , Marlow ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Cristine","family":"K\u00fchnle","sequence":"additional","affiliation":[{"name":"Analytical Services, BioNTech SE , Mainz ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Muik","sequence":"additional","affiliation":[{"name":"ADC-IO & COVID Vaccine Innovation, BioNTech SE , Mainz ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonny Gaby","family":"Lui","sequence":"additional","affiliation":[{"name":"Infectious Disease Vaccines, BioNTech SE , Mainz ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J G T","family":"Vehreschild","sequence":"additional","affiliation":[{"name":"Department II of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital Frankfurt , Frankfurt am Main ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Stephan","sequence":"additional","affiliation":[{"name":"Department II of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital Frankfurt , Frankfurt am Main ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Bushway","sequence":"additional","affiliation":[{"name":"Translational Immunology, BioNTech US , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xu","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd J","family":"Belanger","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Trammel Price","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Liebscher","sequence":"additional","affiliation":[{"name":"Cellular Biomarker and Immunology Research, BioNTech SE , Mainz ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Bailey","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Ltd , Hurley ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Mather","sequence":"additional","affiliation":[{"name":"Worldwide Medical and Safety, Pfizer Inc , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M","family":"Adams","sequence":"additional","affiliation":[{"name":"Clinical Development, BioNTech US , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Shpyro","sequence":"additional","affiliation":[{"name":"Clinical Development, BioNTech US , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Lagkadinou","sequence":"additional","affiliation":[{"name":"Clinical Development, BioNTech US , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"T\u00fcreci","sequence":"additional","affiliation":[{"name":"Global Development Organization, BioNTech SE , Mainz ,","place":["Germany"]},{"name":"Helmholtz Institute for Translational Oncology Mainz (HI-TRON), German Cancer Research Center , Mainz ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3389-8414","authenticated-orcid":false,"given":"Kena A","family":"Swanson","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U\u011fur","family":"\u015eahin","sequence":"additional","affiliation":[{"name":"Global Development Organization, BioNTech SE , Mainz ,","place":["Germany"]},{"name":"Helmholtz Institute for Translational Oncology Mainz (HI-TRON), German Cancer Research Center , Mainz ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Gurtman","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc , Pearl River, NewYork ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"key":"2026072106162491200_ofag310-B1","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1016\/S2352-3018(22)00097-2","article-title":"Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO global clinical platform of COVID-19","volume":"9","author":"Bertagnolio","year":"2022","journal-title":"Lancet HIV"},{"key":"2026072106162491200_ofag310-B2","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1038\/s41598-021-85359-3","article-title":"Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis","volume":"11","author":"Ssentongo","year":"2021","journal-title":"Sci Rep"},{"key":"2026072106162491200_ofag310-B3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41423-023-01087-w","article-title":"The immune response to SARS-CoV-2 in people with HIV","volume":"21","author":"Hoft","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"2026072106162491200_ofag310-B4","author":"Centers for Disease Control and Prevention"},{"key":"2026072106162491200_ofag310-B5","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2026072106162491200_ofag310-B6","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2026072106162491200_ofag310-B7","author":"US Food and Drug Administration"},{"key":"2026072106162491200_ofag310-B8","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.cmi.2021.07.031","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1","volume":"27","author":"Levy","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2026072106162491200_ofag310-B9","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/QAD.0000000000003017","article-title":"Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV","volume":"35","author":"Ruddy","year":"2021","journal-title":"AIDS"},{"key":"2026072106162491200_ofag310-B10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/hiv.13188","article-title":"Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV","volume":"23","author":"Tuan","year":"2022","journal-title":"HIV Med"},{"key":"2026072106162491200_ofag310-B11","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/jmv.27629","article-title":"Immunogenicity and safety of the BNT162b2 COVID-19 mRNA vaccine in PLWH: a monocentric study in Bari, Italy","volume":"94","author":"Milano","year":"2022","journal-title":"J Med Virol"},{"key":"2026072106162491200_ofag310-B12","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1097\/QAD.0000000000003237","article-title":"Surrogate neutralization responses following severe acute respiratory syndrome coronavirus 2 vaccination in people with HIV: comparison between inactivated and mRNA vaccine","volume":"36","author":"Wong","year":"2022","journal-title":"AIDS"},{"key":"2026072106162491200_ofag310-B13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3390\/v14030651","article-title":"Characterization of serum and mucosal SARS-CoV-2-antibodies in HIV-1\u2013infected subjects after BNT162b2 mRNA vaccination or SARS-CoV-2 infection","volume":"14","author":"Schmidt","year":"2022","journal-title":"Viruses"},{"key":"2026072106162491200_ofag310-B14","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/cid\/ciab648","article-title":"The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human immunodeficiency virus (HIV)","volume":"74","author":"Woldemeskel","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026072106162491200_ofag310-B15","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"2026072106162491200_ofag310-B16","author":"Center for Biologics Evaluation and Research"},{"key":"2026072106162491200_ofag310-B17","doi-asserted-by":"crossref","first-page":"100388","DOI":"10.1016\/j.crmeth.2022.100388","article-title":"A universal MHCII technology platform to characterize antigen-specific CD4(+) T cells","volume":"3","author":"Vyasamneni","year":"2023","journal-title":"Cell Rep Methods"},{"key":"2026072106162491200_ofag310-B18","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.chom.2020.04.004","article-title":"An infectious cDNA clone of SARS-CoV-2","volume":"27","author":"Xie","year":"2020","journal-title":"Cell Host Microbe"},{"key":"2026072106162491200_ofag310-B19","doi-asserted-by":"crossref","first-page":"114567","DOI":"10.1016\/j.celrep.2024.114567","article-title":"Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1","volume":"43","author":"Muik","year":"2024","journal-title":"Cell Rep"},{"key":"2026072106162491200_ofag310-B20","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.abn7591","article-title":"Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera","volume":"375","author":"Muik","year":"2022","journal-title":"Science"},{"key":"2026072106162491200_ofag310-B21","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1016\/S2352-3018(21)00157-0","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B\/2A trial","volume":"8","author":"Madhi","year":"2021","journal-title":"Lancet HIV"},{"key":"2026072106162491200_ofag310-B22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","article-title":"Tolerance and exhaustion: defining mechanisms of T cell dysfunction","volume":"35","author":"Schietinger","year":"2014","journal-title":"Trends Immunol"},{"key":"2026072106162491200_ofag310-B23","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"2026072106162491200_ofag310-B24","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/infdis\/jiz205","article-title":"Standard-dose intradermal influenza vaccine elicits cellular immune responses similar to those of intramuscular vaccine in men with and those without HIV infection","volume":"220","author":"Amoah","year":"2019","journal-title":"J Infect Dis"},{"key":"2026072106162491200_ofag310-B25","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1038\/s41467-022-32263-7","article-title":"Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV","volume":"13","author":"Vergori","year":"2022","journal-title":"Nat Commun"},{"key":"2026072106162491200_ofag310-B26","doi-asserted-by":"crossref","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"2026072106162491200_ofag310-B27","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41591-023-02228-4","article-title":"Predicting the efficacy of variant-modified COVID-19 vaccine boosters","volume":"29","author":"Khoury","year":"2023","journal-title":"Nat Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag310\/68566299\/ofag310.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/7\/ofag310\/68566299\/ofag310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/7\/ofag310\/68566299\/ofag310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:16:37Z","timestamp":1784628997000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag310\/8712580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag310","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,21]]},"article-number":"ofag310"}}